Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oramed PharmaceuticalsXTAE:ORMP -5.78%23 PB Ratio is 0.72 as of Aug. 04, 2026, which is 69% below its 10-year median of 2.30. GuruFocus rates XTAE:ORMP with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 1,228 Biotechnology companies, Oramed Pharmaceuticals ranks better than 87.46% on this metric.
The historical rank and industry rank for Oramed Pharmaceuticals's PB Ratio or its related term are showing as below:
XTAE:ORMP'
s PB Ratio Range Over the Past 10 Years
Min: 0.44 Med: 2.3 Max: 9.28
Current: 0.7
During the past 13 years, Oramed Pharmaceuticals's highest PB Ratio was 9.28. The lowest was 0.44. And the median was 2.30.
XTAE:ORMP's PB Ratio is ranked better than 87.46% of 1228
companies
in the Biotechnology industry
Industry Median: 2.765
vs XTAE:ORMP: 0.70
During the past 12 months, Oramed Pharmaceuticals's average Book Value Per Share Growth Rate was 68.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 21.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 12.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Oramed Pharmaceuticals was 80.90% per year. The lowest was -17.50% per year. And the median was 7.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:ORMP vs CAMP, PYXS, ALEC: PB Ratio Comparison
For the Biotechnology subindustry, Oramed Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oramed Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Oramed Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Oramed Pharmaceuticals (XTAE:ORMP) has a PB Ratio of 0.72 as of Aug. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Oramed Pharmaceuticals and its competitors. This is 69% below median its historical median of 2.30. Over the past decade, Oramed Pharmaceuticals' PB Ratio has ranged from 0.44 to 9.28. According to the industry distribution chart, Oramed Pharmaceuticals ranks #154 out of 1228 companies in the Biotechnology industry, placing it in the top 12.5%.
Is Oramed Pharmaceuticals' PB Ratio too high?
Oramed Pharmaceuticals' current PB Ratio of 0.72 is 69% below median its 10-year median of 2.30. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 9.28. The Biotechnology industry median PB Ratio is 2.77. Oramed Pharmaceuticals' value of 0.72 is 74% below this industry median. Based on the distribution chart, Oramed Pharmaceuticals ranks #154 out of 1228 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oramed Pharmaceuticals has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Oramed Pharmaceuticals' PB Ratio compare to CAMP and PYXS?
According to the Biotechnology industry distribution chart, Oramed Pharmaceuticals ranks #154 out of 1228 companies for PB Ratio. This places Oramed Pharmaceuticals in the top 13% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.77. Oramed Pharmaceuticals' value of 0.72 is 74% below this benchmark. Historically, Oramed Pharmaceuticals' own PB Ratio has ranged from 0.44 to 9.28 over the past decade. While the company's 10-year median is 2.30 vs. the industry median of 2.77, Oramed Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.77, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oramed Pharmaceuticals's current PB Ratio of 0.72 is 74% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Oramed Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oramed Pharmaceuticals's current PB Ratio is 0.72, which is 69% below median its own 10-year median of 2.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oramed Pharmaceuticals stock overvalued right now?
Oramed Pharmaceuticals (XTAE:ORMP) has a current PB Ratio of 0.72. The current PB Ratio is 0.72, which is 69% below median its 10-year median of 2.30 and 74% below the Biotechnology industry median of 2.77. Oramed Pharmaceuticals' overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Oramed Pharmaceuticals (XTAE:ORMP), the current PB Ratio is 0.72 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
23GF Score
Get the complete analysis for XTAE:ORMP
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:ORMP has been successfully added to your 
